View Financial HealthTranslational Development Acquisition 配当と自社株買い配当金 基準チェック /06Translational Development Acquisition配当金を支払った記録がありません。主要情報n/a配当利回り-68.1%バイバック利回り総株主利回り-68.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to US$11.50, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 40x in the Capital Markets industry in the US. Total returns to shareholders of 11% over the past year.お知らせ • May 29Prologium Holdings Inc. agreed to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction.Prologium Holdings Inc. ntered into a definitive agreement to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction on May 27, 2026. The transaction values Prologium at approximately $3.8 billion on a pre-money, net cash-free basis. Upon closing, ProLogium will own 92% of the combined company with SPAC & PIPE Investors owning 7%, and SPAC Sponsor owning 1%. Upon completion, the combined company is expected to be named ProLogium Technology and to be listed on Nasdaq under the ticker symbol "PRLG". As part of the transaction, the post-closing board shall consist of nine directors whom one individual is expected to be Michael Hoffman. The consummation of the transaction is conditioned upon, among other things: (i) approval for listing of Prologium Class A Ordinary Shares and warrants contemplated to be listed pursuant to the Business Combination Agreement on Nasdaq; (ii) the absence of any governmental order enjoining, restraining, prohibiting or otherwise making illegal the consummation of the Business Combination; (iii) receipt of the required approval by TDAC shareholders; (iv) receipt of the required approval by Prologium shareholders; (v) the effectiveness of the registration statement to be filed by Prologium under the Securities Act of 1933, as amended; (vi) the Second Merger Surviving Company, as successor to TDAC, having at least $5,000,001 of net tangible assets after the consummation of the Business Combination and the closing of any TDAC shareholder redemptions; (vii) completion of the Recapitalization in accordance with the Business Combination Agreement; (viii) lock-up agreement; (ix) registration rights agreement; and (x) Available Cash, as defined in the Business Combination Agreement, being greater than or equal to $250 million. The boards of directors of both ProLogium and TDAC have approved the Transaction, which is expected to close in the second half of 2026. Venable LLP acted as legal advisor for Translational Development Acquisition Corp. Sullivan & Cromwell LLP acted as legal advisor for Prologium Holdings Inc. BTIG, LLC acted as financial advisor for Translational Development Acquisition Corp. Cohen & Company Capital Markets, LLC acted as financial advisor for Prologium Holdings Inc. LCS & Partners acted as legal advisor for Prologium Holdings Inc.Board Change • May 26High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Michael M. Hoffman is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 24Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million.Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 15,000,000 Price\Range: $10 Discount Per Security: $0.55 Transaction Features: Blank Check Blind Pool Company決済の安定と成長配当データの取得安定した配当: TDAC.Uの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: TDAC.Uの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Translational Development Acquisition 配当利回り対市場TDAC.U 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (TDAC.U)n/a市場下位25% (US)1.3%市場トップ25% (US)4.1%業界平均 (Capital Markets)2.0%アナリスト予想 (TDAC.U) (最長3年)n/a注目すべき配当: TDAC.Uは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: TDAC.Uは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: TDAC.Uの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: TDAC.Uが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/05 06:08終値2026/07/02 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Translational Development Acquisition Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to US$11.50, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 40x in the Capital Markets industry in the US. Total returns to shareholders of 11% over the past year.
お知らせ • May 29Prologium Holdings Inc. agreed to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction.Prologium Holdings Inc. ntered into a definitive agreement to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction on May 27, 2026. The transaction values Prologium at approximately $3.8 billion on a pre-money, net cash-free basis. Upon closing, ProLogium will own 92% of the combined company with SPAC & PIPE Investors owning 7%, and SPAC Sponsor owning 1%. Upon completion, the combined company is expected to be named ProLogium Technology and to be listed on Nasdaq under the ticker symbol "PRLG". As part of the transaction, the post-closing board shall consist of nine directors whom one individual is expected to be Michael Hoffman. The consummation of the transaction is conditioned upon, among other things: (i) approval for listing of Prologium Class A Ordinary Shares and warrants contemplated to be listed pursuant to the Business Combination Agreement on Nasdaq; (ii) the absence of any governmental order enjoining, restraining, prohibiting or otherwise making illegal the consummation of the Business Combination; (iii) receipt of the required approval by TDAC shareholders; (iv) receipt of the required approval by Prologium shareholders; (v) the effectiveness of the registration statement to be filed by Prologium under the Securities Act of 1933, as amended; (vi) the Second Merger Surviving Company, as successor to TDAC, having at least $5,000,001 of net tangible assets after the consummation of the Business Combination and the closing of any TDAC shareholder redemptions; (vii) completion of the Recapitalization in accordance with the Business Combination Agreement; (viii) lock-up agreement; (ix) registration rights agreement; and (x) Available Cash, as defined in the Business Combination Agreement, being greater than or equal to $250 million. The boards of directors of both ProLogium and TDAC have approved the Transaction, which is expected to close in the second half of 2026. Venable LLP acted as legal advisor for Translational Development Acquisition Corp. Sullivan & Cromwell LLP acted as legal advisor for Prologium Holdings Inc. BTIG, LLC acted as financial advisor for Translational Development Acquisition Corp. Cohen & Company Capital Markets, LLC acted as financial advisor for Prologium Holdings Inc. LCS & Partners acted as legal advisor for Prologium Holdings Inc.
Board Change • May 26High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Michael M. Hoffman is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 24Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million.Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 15,000,000 Price\Range: $10 Discount Per Security: $0.55 Transaction Features: Blank Check Blind Pool Company